地西他滨联合HA方案诱导治疗老年急性髓系白血病疗效观察被引量：8

下载PDF

导出

摘要目的观察地西他滨联合HA方案(高三尖杉脂碱+阿糖胞苷)对老年急性髓系白血病(acute myeloid leukemia,AML)患者诱导化疗的效果及安全性。方法回顾性分析2018年1月至2020年2月解放军总医院第七医学中心接受地西他滨联合HA方案诱导化疗的10例老年AML患者,观察其总缓解率及总生存率。结果所有患者均应用地西他滨联合HA方案诱导化疗1~2个周期,3例达完全缓解,4例达部分缓解,1例病情稳定,2例病情进展,总缓解率达70.0%。1例患者放弃治疗后死亡,1例患者在化疗后骨髓抑制期合并严重感染而死亡,2例患者复发后死亡,总生存率达60.0%。9例发生Ⅲ~Ⅳ级骨髓抑制,7例发生严重感染,2例发生败血症,5例发生肺部感染,2例为侵袭性真菌感染,1例患者出现消化道出血,经积极补充血小板、凝血因子后好转,无Ⅲ~Ⅳ级恶心、呕吐及肝功能损害。结论对老年AML患者应用地西他滨联合HA方案诱导化疗,效果显著,耐受性良好。

作者张媛陈鹏李慧敏陈惠仁

机构地区解放军总医院第七医学中心血液病科

出处《中国医刊》 CAS 2021年第1期91-93,共3页 Chinese Journal of Medicine

关键词地西他滨 HA方案急性髓系白血病

分类号 R733.7 [医药卫生—肿瘤]

引文网络
相关文献

参考文献1

1高苏,仇惠英,金正明,唐晓文,傅铮铮,马骁,韩悦,陈苏宁,孙爱宁,吴德沛.地西他滨单药及联合半程和全程CAG方案治疗骨髓增生异常综合征和急性髓系白血病疗效观察[J].中华血液学杂志,2014,35(11):961-965. 被引量：73

二级参考文献13

1Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open- label, phase Ⅲ trial of decitabine versus patient choice, with physician advice, of either supportive care or low- dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia [J]. J Clin Oncol, 2012, 30(21 ):2670-2677. 被引量：1
2Yamada K, Furusawa S, Saito K, et al. Concttrrent use of granu- locyte colony-stimulating factor with low-dose cytosine arabino- side and aclarubicin for previously treated acute myelogenous leukemia: a pilot study[J]. Leukemia,1995, 9 ( 1 ): 10-14. 被引量：1
3Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommen- dations of the International Working Group for diagnosis, stan- dardization of response criteria, treatment outcomes, and report- ing standards for therapeutic trials in acute myeloid leukemia EJ]. J Clin Oncol, 2003, 21 (24):4642-4649. 被引量：1
4Cheson BD, Greenberg PL, Bennett JM, et al. Clinical applica- tion and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia[J]. Blood, 2006, 108(2):419-425. 被引量：1
5Steensma DP, Baer MR, Slack JL, et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastie syndromes: the alternative dosing for out- patient treatment (ADOPT) trial [J]. J Clin Oncol, 2009, 27(23):3842-3848. 被引量：1
6Chowdhury S, Seropian S, Marks PW. Decitabine combined with fractionated gemtuzumab ozogamicin therapy in patients with relapsed or refractory acute myeloid leukemia [J]. Am J Hematol, 2009, 84 (9) :599-600. 被引量：1
7Scandura JM, Roboz GJ, Moh M, et al. Phase 1 study ofepigen- etic priming with decitabine prior to standard induction chemo- therapy for patients with AML[J]. Blood, 2011, 118(6):1472- 1480. 被引量：1
8Song LX, Xu L, Li X, et al. Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia[J]. Ann Hematol, 2012, 91 (12): 1879-1886. 被引量：1
9Qin T, Youssef EM, Jelinek J, et al. Effect of cytarabine and decitabine in combination in human leukemic cell lines IJ]. Clin Cancer Res, 2007, 13( 14):4225-4232. 被引量：1
10Qian S, Duan L. Effect of low-dose cytarabine and aclarubicin in combination with decitabine on the outcome of patients with high-risk myelodysplastic syndromes [G]. 12^th International Symposium on Myelodysplastie Syndromes. Berlin, Germany: Leukemia Research, 2013: S 152-S 153. 被引量：1